TY - JOUR T1 - Early phase of the COVID-19 outbreak in Hungary and post-lockdown scenarios JF - medRxiv DO - 10.1101/2020.06.02.20119313 SP - 2020.06.02.20119313 AU - Gergely Röst AU - Ferenc A. Bartha AU - Norbert Bogya AU - Péter Boldog AU - Attila Dénes AU - Tamás Ferenci AU - Krisztina J. Horváth AU - Attila Juhász AU - Csilla Nagy AU - Tamás Tekeli AU - Zsolt Vizi AU - Beatrix Oroszi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20119313.abstract N2 - COVID-19 epidemic has been suppressed in Hungary due to timely non-pharmaceutical interventions, prompting a huge reduction in the number of contacts and transmission of the virus. This strategy was effective in preventing epidemic growth and reducing the incidence of COVID-19 to low levels. In this report, we present the first epidemiological and statistical analysis of the early phase of the COVID-19 outbreak in Hungary. Then, we establish an age-structured compartmental model to explore alternative post-lockdown scenarios. We incorporate various factors, such as age-specific measures, seasonal effects, and spatial heterogeneity to project the possible peak size and disease burden of a COVID-19 epidemic wave after the current measures are relaxed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was done in the framework of the Hungarian National Development, Research, and Innovation (NKFIH) Fund 2020-2.1.1-ED-2020-00003. Some authors were also supported by EFOP-3.6.1-16-2016-00008 (Zs.V.), NKFIH KKP 129877 (F.B.), NKFIH FK 124016 (T.T.), NKFIH PD 128363 (A.D.), Bolyai Scholarship of HAS (A.D.), TUDFO/47138-1/2019-ITM (F.B., P.B.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project required no such approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe developed software package is available from the link displayed in the manuscript. https://github.com/zsvizi/covid19hun ER -